In a landscape where rare disease treatments often struggle to gain traction, the recent $130 million Series B financing secured by San Diego-based biotech startup Protego Biopharma stands as a beacon of potential. This substantial investment, aimed at advancing the first-in-class drug candidate
Are ERP systems that quietly reconcile invoices and payroll enough when a hospital ward fills overnight, a biologics shipment sits at a congested port, and a payer policy update threatens to choke cash flow before it shows up in the ledger? In the span of a week, a CFO can face staffing choices,
As the landscape of public health continues to evolve, few topics spark as much debate as vaccine safety. Today, we’re diving into this contentious issue with Faisal Zain, a renowned healthcare expert specializing in medical technology. With years of experience in the manufacturing of diagnostic a
Introduction to a Shifting Landscape in Lung Cancer Treatment In the realm of oncology, non-small cell lung cancer (NSCLC) remains a formidable challenge, accounting for a significant portion of cancer diagnoses worldwide, and within this broad category, a small but critical subset—HER2-mutant N
Today, we’re diving into the complex world of biosimilar drugs and regulatory challenges with Faisal Zain, a renowned healthcare expert specializing in medical technology. With his extensive background in the manufacturing of medical devices for diagnostics and treatment, Faisal brings a unique p
Could a single drug approval redefine access to treatment for a rare, life-altering condition? In a landscape where high costs often limit hope for patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals has ignited a spark of change with its FDA-approved RNAi drug,
